PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15638997-0	2005	Microarray analysis of bicalutamide action on telomerase activity, p53 pathway and viability of prostate carcinoma cell lines.	bicalutamide	23-35	tumor protein p53	Homo sapiens	67-70	
15638997-4	2005	Response to bicalutamide in LNCaP cells was represented by downregulation of androgen-regulated genes, activation of the p53 pathway and inhibition of telomerase, which was associated with downregulation of v-myc avian myelocytomatosis viral oncogene homologue (MYC) and telomerase reverse transcriptase subunit.	bicalutamide	12-24	tumor protein p53	Homo sapiens	121-124	
15638997-6	2005	In conclusion, we provide an explanation for telomerase inhibition after androgen receptor blockade in LNCaP cells and we also report activation of the p53 pathway in LNCaP cells and in-vitro sensitivity to bicalutamide of low confluent androgen-insensitive DU145 cells.	bicalutamide	207-219	tumor protein p53	Homo sapiens	152-155	
15638997-8	2005	In particular, activation of the p53 pathway after treatment with 80 microM bicalutamide could justify usage of bicalutamide dosages higher than 150 mg daily in androgen-sensitive carcinoma therapy.	bicalutamide	76-88	tumor protein p53	Homo sapiens	33-36	
15638997-8	2005	In particular, activation of the p53 pathway after treatment with 80 microM bicalutamide could justify usage of bicalutamide dosages higher than 150 mg daily in androgen-sensitive carcinoma therapy.	bicalutamide	112-124	tumor protein p53	Homo sapiens	33-36